Optimal utilization of nonhuman primates for biodefense and emerging pathogens research requires a facility where animals are housed in appropriate biocontainment and research personnel experienced in the methodologies required for infectious disease research and vaccine development. The non-human primate (NHP) Core at the University of Maryland, Baltimore will provide state-of-the-art animal biosafety levels (ABSL) 2 and 3 facilities for biodefense research using nonhuman primates. Currently, our facilities support projects aimed at developing vaccines against anthrax, smallpox and S. dysenteriae 1 vaccines. These projects use NHPs as animal models for studying disease pathogenesis and testing vaccine efficacy and safety. Our facilities fully support biohazard research at ABSL-2 and 3 levels and meet all NIH/CDC guidelines. Our expert personnel will provide consultation services to investigators planning to use the NHP core for biohazard studies. We will make available our extensive experience in the utilization of NHPs for pathogenesis research and vaccine development for various CDC category A, B and C agents. Hence, the NHP core will be a very important component to support proposals aimed at developing innovative therapeutics against bioterrorism agents.

Public Health Relevance

All biohazard projects using non-human primates as animal models for biomedical research require special support in terms of animal housing, biocontainment and veterinary medical support. This proposal is aimed at supporting such projects by providing core facilities to investigators who propose to carry out studies focused on developing therapeutics against infectious agents. Our state-of-the-art animal biosafety levels 2 and 3 facilities are fully capable of supporting biohazard studies. Our experienced staff can provide valuable veterinary and research support to investigators who propose to use NHPs in these studies

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Freedman, John C; Theoret, James R; Wisniewski, Jessica A et al. (2015) Clostridium perfringens type A-E toxin plasmids. Res Microbiol 166:264-79
Li, Jihong; McClane, Bruce A (2014) Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease. Infect Immun 82:4620-30
Moy, Ryan H; Gold, Beth; Molleston, Jerome M et al. (2014) Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammals. Immunity 40:51-65
Cuevas, Christian D; Ross, Susan R (2014) Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain. J Virol 88:7703-14
Boyd, Mary Adetinuke; Tennant, Sharon M; Saague, Venant A et al. (2014) Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines. Clin Vaccine Immunol 21:712-21
Su, Yi-Hsuan; Tsegaye, Mikiyas; Varhue, Walter et al. (2014) Quantitative dielectrophoretic tracking for characterization and separation of persistent subpopulations of Cryptosporidium parvum. Analyst 139:66-73
Xu, Jie; Cherry, Sara (2014) Viruses and antiviral immunity in Drosophila. Dev Comp Immunol 42:67-84
Uzal, Francisco A; Freedman, John C; Shrestha, Archana et al. (2014) Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiol 9:361-77
Weir, Dawn L; Laing, Eric D; Smith, Ina L et al. (2014) Host cell virus entry mediated by Australian bat lyssavirus G envelope glycoprotein occurs through a clathrin-mediated endocytic pathway that requires actin and Rab5. Virol J 11:40
Weir, Dawn L; Annand, Edward J; Reid, Peter A et al. (2014) Recent observations on Australian bat lyssavirus tropism and viral entry. Viruses 6:909-26

Showing the most recent 10 out of 299 publications